These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15308639)

  • 21. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?
    Li Y; Prives C
    Oncogene; 2007 Apr; 26(15):2220-5. PubMed ID: 17401431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inactivation of retinoblastoma (RB) tumor suppressor by oncogenic isoforms of the p53 family member p73.
    Stiewe T; Stanelle J; Theseling CC; Pollmeier B; Beitzinger M; Pützer BM
    J Biol Chem; 2003 Apr; 278(16):14230-6. PubMed ID: 12584188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p73-mediated chemosensitivity: a preferential target of oncogenic mutant p53.
    Strano S; Blandino G
    Cell Cycle; 2003; 2(4):348-9. PubMed ID: 12851488
    [No Abstract]   [Full Text] [Related]  

  • 24. Structure, function and regulation of p63 and p73.
    Levrero M; De Laurenzi V; Costanzo A; Gong J; Melino G; Wang JY
    Cell Death Differ; 1999 Dec; 6(12):1146-53. PubMed ID: 10637429
    [TBL] [Abstract][Full Text] [Related]  

  • 25. p53 and its homologues, p63 and p73, induce a replicative senescence through inactivation of NF-Y transcription factor.
    Jung MS; Yun J; Chae HD; Kim JM; Kim SC; Choi TS; Shin DY
    Oncogene; 2001 Sep; 20(41):5818-25. PubMed ID: 11593387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MDM2 and MDMX can interact differently with ARF and members of the p53 family.
    Wang X; Arooz T; Siu WY; Chiu CH; Lau A; Yamashita K; Poon RY
    FEBS Lett; 2001 Feb; 490(3):202-8. PubMed ID: 11223036
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A naturally occurring p73 mutation in a p73-p53 double-mutant lung cancer cell line encodes p73 alpha protein with a dominant-negative function.
    Huqun ; Endo Y; Xin H; Takahashi M; Nukiwa T; Hagiwara K
    Cancer Sci; 2003 Aug; 94(8):718-24. PubMed ID: 12901798
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential regulation of transcription and induction of programmed cell death by human p53-family members p63 and p73.
    Dietz S; Rother K; Bamberger C; Schmale H; Mössner J; Engeland K
    FEBS Lett; 2002 Aug; 525(1-3):93-9. PubMed ID: 12163168
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dysregulated ΔNp63α negatively regulates the maspin promoter in keratinocytes via blocking endogenous p73 binding.
    King KE; Reddi DM; Ponnamperuma RM; Gerdes M; Weinberg WC
    Mol Carcinog; 2014 Sep; 53(9):698-710. PubMed ID: 23475637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic prospects for p73 and p63: rising from the shadow of p53.
    Vilgelm A; El-Rifai W; Zaika A
    Drug Resist Updat; 2008; 11(4-5):152-63. PubMed ID: 18801697
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation and activation of p53 and its family members.
    Lohrum MA; Vousden KH
    Cell Death Differ; 1999 Dec; 6(12):1162-8. PubMed ID: 10637431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temperature-sensitive mutants of p53 homologs.
    Pochampally R; Li C; Lu W; Chen L; Luftig R; Lin J; Chen J
    Biochem Biophys Res Commun; 2000 Dec; 279(3):1001-10. PubMed ID: 11162465
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The emerging p53 gene family.
    Kaelin WG
    J Natl Cancer Inst; 1999 Apr; 91(7):594-8. PubMed ID: 10203277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Notch and the p53 clan of transcription factors.
    Roemer K
    Adv Exp Med Biol; 2012; 727():223-40. PubMed ID: 22399351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. E1B 55-kilodalton oncoproteins of adenovirus types 5 and 12 inactivate and relocalize p53, but not p51 or p73, and cooperate with E4orf6 proteins to destabilize p53.
    Wienzek S; Roth J; Dobbelstein M
    J Virol; 2000 Jan; 74(1):193-202. PubMed ID: 10590106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Conformational stability and activity of p73 require a second helix in the tetramerization domain.
    Coutandin D; Löhr F; Niesen FH; Ikeya T; Weber TA; Schäfer B; Zielonka EM; Bullock AN; Yang A; Güntert P; Knapp S; McKeon F; Ou HD; Dötsch V
    Cell Death Differ; 2009 Dec; 16(12):1582-9. PubMed ID: 19763140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar dna-binding profiles in vivo.
    Yang A; Zhu Z; Kettenbach A; Kapranov P; McKeon F; Gingeras TR; Struhl K
    PLoS One; 2010 Jul; 5(7):e11572. PubMed ID: 20644729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. P53 family: at the crossroads in cancer therapy.
    Alsafadi S; Tourpin S; André F; Vassal G; Ahomadegbe JC
    Curr Med Chem; 2009; 16(32):4328-44. PubMed ID: 19754415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How many mutant p53 molecules are needed to inactivate a tetramer?
    Chan WM; Siu WY; Lau A; Poon RY
    Mol Cell Biol; 2004 Apr; 24(8):3536-51. PubMed ID: 15060172
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interaction of regulators Mdm2 and Mdmx with transcription factors p53, p63 and p73.
    Zdzalik M; Pustelny K; Kedracka-Krok S; Huben K; Pecak A; Wladyka B; Jankowski S; Dubin A; Potempa J; Dubin G
    Cell Cycle; 2010 Nov; 9(22):4584-91. PubMed ID: 21088494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.